MCID: CLR137
MIFTS: 35

Clear Cell Adenocarcinoma of the Ovary

Categories: Reproductive diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Clear Cell Adenocarcinoma of the Ovary

MalaCards integrated aliases for Clear Cell Adenocarcinoma of the Ovary:

Name: Clear Cell Adenocarcinoma of the Ovary 59
Ovarian Clear Cell Adenocarcinoma 59 73

Classifications:



External Ids:

Orphanet 59 ORPHA398971
ICD10 via Orphanet 34 C56

Summaries for Clear Cell Adenocarcinoma of the Ovary

MalaCards based summary : Clear Cell Adenocarcinoma of the Ovary, also known as ovarian clear cell adenocarcinoma, is related to ovarian clear cell adenocarcinoma and adenocarcinoma. An important gene associated with Clear Cell Adenocarcinoma of the Ovary is GPC3 (Glypican 3), and among its related pathways/superpathways are Small cell lung cancer and Androgen receptor signaling pathway. The drugs Carboplatin and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include ovary, endothelial and skin.

Related Diseases for Clear Cell Adenocarcinoma of the Ovary

Diseases related to Clear Cell Adenocarcinoma of the Ovary via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 11)
# Related Disease Score Top Affiliating Genes
1 ovarian clear cell adenocarcinoma 12.4
2 adenocarcinoma 10.6
3 clear cell adenocarcinoma 10.6
4 adenofibroma 10.0
5 endometriosis 10.0
6 ovarian cancer 1 9.9
7 clear cell adenofibroma 9.9
8 peritonitis 9.9
9 bowenoid papulosis 9.8 CCND1 CCNE1
10 gastrointestinal system cancer 9.6 CCND1 GPC3
11 galactosialidosis 9.5 NEU1 NEU3

Graphical network of the top 20 diseases related to Clear Cell Adenocarcinoma of the Ovary:



Diseases related to Clear Cell Adenocarcinoma of the Ovary

Symptoms & Phenotypes for Clear Cell Adenocarcinoma of the Ovary

Drugs & Therapeutics for Clear Cell Adenocarcinoma of the Ovary

Drugs for Clear Cell Adenocarcinoma of the Ovary (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 49)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Carboplatin Approved Phase 3,Phase 1,Phase 2 41575-94-4 10339178 498142 38904
2
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
3
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
4
Gemcitabine Approved Phase 3 95058-81-4 60750
5
Doxorubicin Approved, Investigational Phase 2, Phase 3,Phase 3 23214-92-8 31703
6
Olaparib Approved Phase 3,Phase 2 763113-22-0 23725625
7
Topotecan Approved, Investigational Phase 2, Phase 3 119413-54-6, 123948-87-8 60700
8
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
9
Cediranib Investigational Phase 3,Phase 2 288383-20-0 9933475
10
Doxil Approved June 1999 Phase 2, Phase 3,Phase 3 31703
11
Maleic acid Experimental Phase 3,Phase 2 110-16-7 444266
12 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
13 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
14 Mitogens Phase 3,Phase 2,Phase 1
15 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
16 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
17 Immunoglobulin G Phase 3,Phase 2,Phase 1
18 Antibodies Phase 3,Phase 2,Phase 1
19 Immunoglobulins Phase 3,Phase 2,Phase 1
20 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
21 Antimitotic Agents Phase 3,Phase 2,Phase 1
22 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
23 Micronutrients Phase 3
24 Topoisomerase Inhibitors Phase 2, Phase 3,Phase 3
25 Trace Elements Phase 3
26 Anti-Bacterial Agents Phase 2, Phase 3,Phase 3
27 Antibiotics, Antitubercular Phase 2, Phase 3,Phase 3
28 Poly(ADP-ribose) Polymerase Inhibitors Phase 3,Phase 2,Phase 1
29 Immunosuppressive Agents Phase 3,Phase 2
30 Anti-Infective Agents Phase 3
31 Protein Kinase Inhibitors Phase 3,Phase 2
32 Antimetabolites Phase 3
33 Antiviral Agents Phase 3
34 Antimetabolites, Antineoplastic Phase 3
35 Carotenoids Phase 3
36 taxane Phase 3
37 topoisomerase I inhibitors Phase 2, Phase 3
38
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
39
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
40
Iodine Approved, Investigational Phase 1, Phase 2 7553-56-2 807
41
Pembrolizumab Approved Phase 2 1374853-91-4
42
Xylometazoline Approved, Investigational Phase 2 526-36-3 5709
43 Alkylating Agents Phase 2
44 Antirheumatic Agents Phase 2
45 Antineoplastic Agents, Alkylating Phase 2
46 tyrosine Nutraceutical Phase 2
47
Bortezomib Approved, Investigational Phase 1 179324-69-7 387447 93860
48
Cisplatin Approved Phase 1 15663-27-1 84093 441203 2767
49
Veliparib Investigational Phase 1 912444-00-9 11960529

Interventional clinical trials:

(show all 18)
# Name Status NCT ID Phase Drugs
1 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
2 Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
3 Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02446600 Phase 3 Carboplatin;Cediranib Maleate;Gemcitabine Hydrochloride;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride
4 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT00719303 Phase 3
5 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3 Paclitaxel;Paclitaxel Poliglumex
6 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Suspended NCT02502266 Phase 2, Phase 3 Cediranib Maleate;Olaparib;Paclitaxel;Pegylated Liposomal Doxorubicin Hydrochloride;Topotecan Hydrochloride
7 Sunitinib® in Patients With Recurrent Ovarian Clear Cell Carcinoma Unknown status NCT01824615 Phase 2 Sunitinib
8 A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell Adenocarcinomas Recruiting NCT03405454 Phase 2 durvalumab;standard chemotherapy
9 MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer Recruiting NCT02068794 Phase 1, Phase 2
10 Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02853318 Phase 2 Cyclophosphamide
11 Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02713386 Phase 1, Phase 2 Carboplatin;Paclitaxel;Ruxolitinib Phosphate
12 Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer Active, not recruiting NCT00979992 Phase 2 Sunitinib Malate
13 Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT02315430 Phase 2 Cabozantinib S-malate
14 Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Active, not recruiting NCT00888615 Phase 2 Elesclomol Sodium;Paclitaxel
15 Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Completed NCT01074411 Phase 1 Bortezomib;Carboplatin
16 Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Active, not recruiting NCT00989651 Phase 1 Carboplatin;Cisplatin;Paclitaxel;Veliparib
17 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers Suspended NCT02020707 Phase 1 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
18 Ovarian Clear Cell Adenocarcinoma Review Completed NCT02129036

Search NIH Clinical Center for Clear Cell Adenocarcinoma of the Ovary

Genetic Tests for Clear Cell Adenocarcinoma of the Ovary

Anatomical Context for Clear Cell Adenocarcinoma of the Ovary

MalaCards organs/tissues related to Clear Cell Adenocarcinoma of the Ovary:

41
Ovary, Endothelial, Skin, Spleen, Lymph Node

Publications for Clear Cell Adenocarcinoma of the Ovary

Articles related to Clear Cell Adenocarcinoma of the Ovary:

(show top 50) (show all 113)
# Title Authors Year
1
Synchronous occurrence of primary right ovarian endometrioid adenocarcinoma and primary left ovarian clear cell adenocarcinoma: A case report. ( 29979406 )
2018
2
Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma with fetal gut differentiation: a rare case report and literature review. ( 29933751 )
2018
3
Skin metastases in ovarian clear cell adenocarcinoma: a case report and a review of the literature. ( 29184869 )
2017
4
Vesical clear cell adenocarcinoma arising from endometriosis: A mullerian tumor, indistinguishable from ovarian clear cell adenocarcinoma. ( 27660815 )
2016
5
Effect of ARID1A/BAF250a expression on carcinogenesis and clinicopathological factors in pure-type clear cell adenocarcinoma of the ovary. ( 27699033 )
2016
6
Combined benign Brenner tumor and clear cell adenocarcinoma of the ovary. ( 26150073 )
2015
7
Low Expression of S100P Is Associated With Poor Prognosis in Patients With Clear Cell Adenocarcinoma of the Ovary. ( 26397155 )
2015
8
Somatic copy number alterations associated with Japanese or endometriosis in ovarian clear cell adenocarcinoma. ( 25658832 )
2015
9
Clinicopathological heterogeneity in ovarian clear cell adenocarcinoma: a study on individual therapy practice. ( 25398420 )
2014
10
Mass Spectrometric Analysis of the Phosphorylation Levels of the SWI/SNF Chromatin Remodeling/Tumor Suppressor Proteins ARID1A and Brg1 in Ovarian Clear Cell Adenocarcinoma Cell Lines. ( 25083560 )
2014
11
Non-diethylstilbestrol exposed vaginal clear cell adenocarcinoma has a common molecular profile with ovarian clear cell adenocarcinoma: A case report. ( 26082939 )
2014
12
Alpha-fetoprotein-producing ovarian clear cell adenocarcinoma simulating fetal gut in a postmenopausal woman. ( 24707459 )
2014
13
Impact of surgical staging in stage I clear cell adenocarcinoma of the ovary. ( 25010038 )
2014
14
Defect of tropomyosin-related kinase B isotype expression in ovarian clear cell adenocarcinoma. ( 24815386 )
2014
15
Splenic metastasis of ovarian clear cell adenocarcinoma: A case report and review of the literature. ( 24669262 )
2014
16
Napsin A is a specific marker for ovarian clear cell adenocarcinoma. ( 24721826 )
2014
17
Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423. ( 24504419 )
2014
18
Patterns of recurrence and role of pelvic radiotherapy in ovarian clear cell adenocarcinoma. ( 25275661 )
2014
19
Maximum standardized uptake value of fluorodeoxyglucose positron emission tomography/computed tomography is a prognostic factor in ovarian clear cell adenocarcinoma. ( 24987918 )
2014
20
Establishment and characterization of a novel ovarian clear cell adenocarcinoma cell line, TU-OC-1, with a mutation in the PIK3CA gene. ( 23430509 )
2013
21
Secretome-based identification of TFPI2, a novel serum biomarker for detection of ovarian clear cell adenocarcinoma. ( 23805888 )
2013
22
Expression of chromobox homolog 7 (CBX7) is associated with poor prognosis in ovarian clear cell adenocarcinoma via TRAIL-induced apoptotic pathway regulation. ( 24375438 )
2013
23
Alterations of hypoxia-induced factor signaling pathway due to mammalian target of rapamycin (mTOR) suppression in ovarian clear cell adenocarcinoma: in vivo and in vitro explorations for clinical trial. ( 23899586 )
2013
24
Integrative analysis of copy number alteration and gene expression profiling in ovarian clear cell adenocarcinoma. ( 23726144 )
2013
25
Clear cell adenocarcinoma of the ovary with a sarcoid reaction in the spleen and regional lymph nodes: A case report. ( 24371694 )
2013
26
Met is the most frequently amplified gene in endometriosis-associated ovarian clear cell adenocarcinoma and correlates with worsened prognosis. ( 23469222 )
2013
27
Annexin A4 is involved in proliferation, chemo-resistance and migration and invasion in ovarian clear cell adenocarcinoma cells. ( 24244679 )
2013
28
A recurrence-predicting prognostic factor for patients with ovarian clear-cell adenocarcinoma at reproductive age. ( 24306200 )
2013
29
Stathmin Regulates Hypoxia-Inducible Factor-1I+ Expression through the Mammalian Target of Rapamycin Pathway in Ovarian Clear Cell Adenocarcinoma. ( 23819061 )
2013
30
Nedaplatin and irinotecan combination therapy is equally effective and less toxic than cisplatin and irinotecan for patients with primary clear cell adenocarcinoma of the ovary and recurrent ovarian carcinoma. ( 23162643 )
2012
31
ACTN4 gene amplification and actinin-4 protein overexpression drive tumour development and histological progression in a high-grade subset of ovarian clear-cell adenocarcinomas. ( 22348389 )
2012
32
Promoter methylation status of HIN-1 associated with outcomes of ovarian clear cell adenocarcinoma. ( 22871047 )
2012
33
[DNA damage response in ovarian clear cell adenocarcinoma]. ( 22812231 )
2012
34
PIK3CA mutations and loss of ARID1A protein expression are early events in the development of cystic ovarian clear cell adenocarcinoma. ( 22120431 )
2012
35
Two cases of ovarian clear cell adenocarcinoma producing estradiol. ( 22360511 )
2012
36
Histological grading of ovarian clear cell adenocarcinoma: proposal for a simple and reproducible grouping system based on tumor growth architecture. ( 22317866 )
2012
37
Aberrant expression of the mammalian target of rapamycin, hypoxia-inducible factor-1I+, and glucose transporter 1 in the development of ovarian clear-cell adenocarcinoma. ( 22498943 )
2012
38
Accumulative copy number increase of MET drives tumor development and histological progression in a subset of ovarian clear-cell adenocarcinomas. ( 21983935 )
2012
39
Clear cell adenocarcinoma of the ovary arising in atypical endometriosis: a report of eight cases. ( 21594603 )
2012
40
Analysis of mTOR inhibition-involved pathway in ovarian clear cell adenocarcinoma. ( 21614172 )
2011
41
Biological significance of plasminogen activator inhibitor-1 expression in ovarian clear cell adenocarcinoma. ( 22335020 )
2011
42
Validation of the histologic grading for ovarian clear cell adenocarcinoma: a retrospective multi-institutional study by the Japan Clear Cell Carcinoma Study Group. ( 21293288 )
2011
43
Gene amplification and protein overexpression of MET are common events in ovarian clear-cell adenocarcinoma: their roles in tumor progression and prognostication of the patient. ( 21478826 )
2011
44
Re-expression of estrogen receptor I^ inhibits the proliferation and migration of ovarian clear cell adenocarcinoma cells. ( 21874257 )
2011
45
Clear cell adenocarcinoma with a component of poorly differentiated histology: a poor prognostic subgroup of ovarian clear cell adenocarcinoma. ( 21804390 )
2011
46
PIK3CA mutation is an early event in the development of endometriosis-associated ovarian clear cell adenocarcinoma. ( 21735444 )
2011
47
IGFBP-1 is expressed specifically in ovarian clear cell adenocarcinoma. ( 21457161 )
2011
48
Wild-type p53 enhances annexin IV gene expression in ovarian clear cell adenocarcinoma. ( 21348943 )
2011
49
Relationship between ABCF2 expression and response to chemotherapy or prognosis in clear cell adenocarcinoma of the ovary. ( 20973270 )
2010
50
Promoter methylation of sFRP5 in patients with ovarian clear cell adenocarcinoma. ( 20486992 )
2010

Variations for Clear Cell Adenocarcinoma of the Ovary

Expression for Clear Cell Adenocarcinoma of the Ovary

Search GEO for disease gene expression data for Clear Cell Adenocarcinoma of the Ovary.

Pathways for Clear Cell Adenocarcinoma of the Ovary

GO Terms for Clear Cell Adenocarcinoma of the Ovary

Cellular components related to Clear Cell Adenocarcinoma of the Ovary according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lysosomal lumen GO:0043202 8.96 GPC3 NEU1
2 cyclin-dependent protein kinase holoenzyme complex GO:0000307 8.62 CCND1 CCNE1

Biological processes related to Clear Cell Adenocarcinoma of the Ovary according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of transcription by RNA polymerase II GO:0000122 9.46 CCND1 CCNE1 IFI27 POU6F1
2 G1/S transition of mitotic cell cycle GO:0000082 9.37 CCND1 CCNE1
3 glycosphingolipid metabolic process GO:0006687 9.32 NEU1 NEU3
4 regulation of protein kinase activity GO:0045859 9.26 CCND1 CCNE1
5 oligosaccharide catabolic process GO:0009313 8.96 NEU1 NEU3
6 ganglioside catabolic process GO:0006689 8.62 NEU1 NEU3

Molecular functions related to Clear Cell Adenocarcinoma of the Ovary according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hydrolase activity, acting on glycosyl bonds GO:0016798 9.4 NEU1 NEU3
2 cyclin-dependent protein serine/threonine kinase regulator activity GO:0016538 9.37 CCND1 CCNE1
3 exo-alpha-sialidase activity GO:0004308 9.32 NEU1 NEU3
4 exo-alpha-(2->8)-sialidase activity GO:0052796 9.26 NEU1 NEU3
5 exo-alpha-(2->6)-sialidase activity GO:0052795 9.16 NEU1 NEU3
6 exo-alpha-(2->3)-sialidase activity GO:0052794 8.96 NEU1 NEU3
7 alpha-sialidase activity GO:0016997 8.62 NEU1 NEU3

Sources for Clear Cell Adenocarcinoma of the Ovary

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....